Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease

Clinical Chemistry

Volumn 53, Issue 4, 2007, Pages 679-685

  Jones, Gregory T ^a,c   Van Rij, Andre M ^a   Cole, Jennifer ^a   Williams, Michael J A ^a   Bateman, Emma H ^a   Marcovina, Santica M ^b   Deng, Meiying ^a   McCormick, Sally P A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANAMNESIS; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFOUNDING VARIABLE; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; RISK FACTOR; SMOKING; STROKE;

AGED; AORTIC ANEURYSM, ABDOMINAL; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; PERIPHERAL VASCULAR DISEASES; PLASMA; REFERENCE VALUES; RISK;

EID: 34147211127     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.079947     Document Type: Article

References (43)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Lusis AJ. Atherosclerosis. Nature 2000;407:233-41.
3. Kannel WB, D'Agostino RB, Sullivan L, Wilson PW. Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004;148:16-26.
4. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-8.
5. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 1998;19 Suppl A:A2-11.
6. Jenkins DJ, Kendall CW, Marchie A, Faulkner DA, Wong JM, de Souza R, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290:502-10.
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
8. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205.
9. Utermann G. The mysteries of lipoprotein (a). Science 1989;246:904-10.
10. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem 2003;49:1785-96.
11. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, et al. Effects of the apolipoprotein (a) size polymorphism on the lipoprotein (a) concentration in 7 ethnic groups. Hum Genet 1991;86:607-14.
12. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
13. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein (a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37:333-43.
14. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163:377-84.
15. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999;45:1039-46.
16. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-61.
17. Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. J Vasc Surg 1996;23:53-61, discussion-3.
18. Cheng SW, Ting AC, Wong J. Lipoprotein (a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur J Vasc Endovasc Surg 1997;14:17-23.
19. Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg 1993;7:446-51.
20. Peng DQ, Zhao SP, Wang JL. Lipoprotein (a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 1999;6:1-6.
21. Milionis HJ, Filippatos TD, Loukas T, Bairaktari ET, Tselepis AD, Elisaf MS. Serum lipoprotein (a) levels and apolipoprotein (a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 2006;187:170-6.
22. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8.
23. Norrgard O, Angquist KA, Dahlen G. High concentrations of Lp (a) lipoprotein in serum are common among patients with abdominal aortic aneurysms. Int Angiol 1988;7:46-9.
24. Sofi F, Marcucci R, Giusti B, Pratesi G, Lari B, Sestini I, et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost 2005;94:1094-8.
25. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein (a) and the risk of myocardial infarction. Jama 1993;270:2195-9.
26. Wang W, Hu D, Lee ET, Fabsitz RR, Welty TK, Robbins DC, et al. Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol 2002;12:107-14.
27. Lindholt JS, Heegaard NH, Vammen S, Fasting H, Henneberg EW, Heickendorff L. Smoking, but not lipids, lipoprotein (a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2001;21:51-6.
28. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995;273:1269-73.
29. Danesh J, Collins R, Peto R. Lipoprotein (a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
30. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995;41:246-55.
31. Jones GT, Harris EL, Phillips LV, van Rij AM. The Methylenetetrahydrofolate Reductase C677T Polymorphism Does Not Associate with Susceptibility to Abdominal Aortic Aneurysm. Eur J Vasc Endovasc Surg 2005;30:137-42.
32. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem 1996;42:436-9.
33. Marcovina SM, Albers JJ, Scanu AM, Kennedy H, Giaculli F, Berg K, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein (a). Clin Chem 2000;46:1956-67.
34. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
35. Marcovina SM, Albers JJ, Wijsman E, Zhang ZH, Chapman NH, Kennedy H. Differences in Lp (a) concentrations and apo (a) polymorphs between Black and White Americans. J Lipid Res 1996;37:2569-85.
36. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U; discussion 86U.
37. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp (a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57.
38. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003;14:361-6.
39. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318-26.
40. Saito S, Zempo N, Yamashita A, Takenaka H, Fujioka K, Esato K. Matrix metalloproteinase expressions in arteriosclerotic aneurysmal disease. Vasc Endovascular Surg 2002;36:1-7.
41. Nowak-Gottl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, et al. Increased lipoprotein (a) is an important risk factor for venous thromboembolism in childhood. Circulation 1999;100:743-8.
42. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, et al. Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. Eur J Clin Invest 2006;36:91-7.
43. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein (a), measured with an assay independent of apolipoprotein (a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006;296:1363-70.